Eneda Toska, PhD

Eneda Toska, PhD Memorial Sloan Kettering Cancer Center Eneda Tokae, PhD Mutations in the PIK3CA gene are the most frequent genomic alterations in estrogen receptor (ER)-positive breast cancers. One treatment strategy is the use of drugs that inhibit the gene’s signaling pathway—however, many patients eventually become resistant to this type of therapy. [...]

Eneda Toska, PhD2017-07-05T11:41:21-05:00

Daniel G. Stover, MD

Daniel G. Stover, MD Dana-Farber Cancer Institute Daniel G Stover, M.D. The host immune system is critical in the control and elimination of tumors in many cancer types. In breast cancer, tumor infiltrating immune cells have been associated with both response to chemotherapy and overall outcome for patients. Understanding what immune cell [...]

Daniel G. Stover, MD2017-07-05T11:42:03-05:00

Mihriban Karaayvaz, PhD

Mihriban Karaayvaz, PhD Mass General Hospital Cancer Center Mihriban Karaayvaz, PhD Making a major impact on the incidence and lethality of breast cancer will require a detailed understanding of the early events in breast cancer development, particularly in women who are at the highest risk of developing these cancers such as those [...]

Mihriban Karaayvaz, PhD2017-07-05T11:42:32-05:00

Jean Albrengues, PhD

Jean Albrengues, PhD PhD Cold Spring Harbor Laboratories Jean Albrengues, PhD Dr. Albrengues’ 2016 Terri Brodeur Breast Cancer Foundation fellowship award focuses on the regulation of breast cancer dormancy by the tumor microenvironment. Metastatic breast cancer relapse occurring years after a seemingly successful treatment is preceded by an interlude, termed dormancy, when [...]

Jean Albrengues, PhD2017-07-05T11:44:29-05:00